Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06445400
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 28
- Registration Number
- NCT06441890
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 236
- Registration Number
- NCT06439225
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06439693
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 500
- Registration Number
- NCT06430411
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Jinghui Wang
- Target Recruit Count
- 30
- Registration Number
- NCT06421298
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06394713
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Qian Qin
- Target Recruit Count
- 64
- Registration Number
- NCT06392841
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 40
- Registration Number
- NCT06387056
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 548
- Registration Number
- NCT06382129
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.